Baird Medical Stock Price, News & Analysis

Baird Medical (NASDAQ: BDMD) announced clinical adoption of its Microwave Ablation (MWA) system at Elk Medical, a private endocrinology practice in Brooklyn, New York, on Oct. 27, 2025. Dr. Kazeem performed nine MWA procedures treating large thyroid nodules as a non-surgical alternative. The clinic reported that these initial procedures have been successfully reimbursed by Medicare, which the company described as an encouraging early step toward broader patient access and potential economic viability for MWA therapy in a key U.S. market.

Baird Medical (NASDAQ: BDMD) announced the company’s first successful microwave ablation (MWA) liver tumor procedure in Bangladesh on Oct 23, 2025. The treatment was performed at USB Hospital in Uttara, Dhaka, by Dr. Mofazzal Sharif Rasel and team on a 65-year-old patient with a 6 cm liver tumor, who is reported to be recovering well. The event represents a commercial and clinical adoption milestone for Baird Medical in South Asia and underscores the company’s stated focus on expanding global access to minimally invasive tumor therapies through strategic clinician and institution partnerships.

Baird Medical (NASDAQ: BDMD) participated in an International Thyroid Microwave Ablation Workshop at Hospital Canselor Tuanku Muhriz (HCTM), National University of Malaysia on October 1–2, 2025.

Led by Proctor Dr. Shuhang Xu, endocrinologist at Jiangsu Provincial Hospital, with HCTM surgeons Dr. Adi Syazni and Prof. Shahrun Niza, the two-day program combined theoretical lectures, complex case discussions, and hands-on training with mannequins and live patients to advance physician MWA skills and support global adoption of minimally invasive therapy.

Baird Medical (NASDAQ: BDMD) participated in a two-day Thyroid Microwave Ablation Workshop at Hospital Canselor Tuanku Muhriz, National University of Malaysia on Oct 1–2, 2025.

The immersive program combined lectures, complex case discussions and hands-on training with mannequins and live patient cases led by Proctor Dr. Shuhang Xu and HCTM faculty Dr. Adi Syazni and Prof. Shahrun Niza. Baird Medical supplied expertise and support to advance physician skills in minimally invasive Microwave Ablation (MWA) and to promote wider clinical adoption of MWA therapy in the region.

Baird Medical (NASDAQ: BDMD) participated in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism held in Beijing on October 17-18, 2025 at the China-Japan Friendship Hospital.

Chaired by Prof. Ming'an Yu, the workshop featured live procedures, clinical exchanges, and advanced technique discussions. Baird Medical said its presence highlights a commitment to international collaboration, sharing best practices for Microwave Ablation (MWA), and advancing minimally invasive thyroid care.

Baird Medical (NASDAQ: BDMD) announced its microwave ablation (MWA) system was successfully used in two minimally invasive procedures at UCSF Health on Oct 16, 2025.

Interventional radiologist Dr. Alexander Lam treated two patients with benign thyroid nodules measuring 5.0 cm and 6.5 cm, avoiding surgery. Active treatment time averaged less than 25 minutes per case; both patients remained comfortable under local anesthesia and reported minimal pain. The company said the cases demonstrate MWA as a non-surgical option that can preserve thyroid function and reduce surgical risks.

Baird Medical (NASDAQ: BDMD) highlighted a Johns Hopkins University cost-utility analysis presented at the American Thyroid Association meeting showing that adding transcutaneous thyroid nodule ablation (TNA) to care pathways produced projected cost savings and quality-of-life gains versus surgery or observation.

The health economic model estimated $1,641 per-patient savings for benign nodules and $380 savings for thyroid microcarcinomas over a five-year horizon, while also reporting gains in quality-adjusted life years (QALYs). The study found TNA was the preferred strategy in a substantial majority of modeled scenarios. Baird Medical supported the research and said it will evaluate the findings for potential use in future patient-care developments.

Baird Medical (NASDAQ: BDMD) concluded participation at the ACS Clinical Congress 2025 (October 5–7), showcasing its minimally invasive microwave ablation (MWA) systems to a global surgical audience.

At the exhibit, the company's advanced MWA technology drew significant surgeon interest across specialties, with live demonstrations focused on applications for thyroid nodules, breast disease, and other conditions. The company reported high engagement and renewed discussions with surgical and interventional leaders from leading institutions, and said it will pursue expanded U.S. and international partnerships building on congress momentum.

Baird Medical (NASDAQ: BDMD) is exhibiting at the American College of Surgeons Clinical Congress 2025 in Chicago from October 5–7, 2025. The company is at Booth 1061 presenting live, hands-on demonstrations of its minimally invasive Microwave Ablation (MWA) devices. Demonstrations highlight precision and efficiency for treating thyroid nodules, breast disease, and liver cancer, and aim to engage surgeons and clinical leaders on expanding MWA applications in interventional medicine. Participation underscores Baird Medical's focus on clinical collaboration and advancing patient care through its MWA technology.